BMS-911543JAK2 inhibitor,selective small molecule CAS# 1271022-90-2 |
- Lestaurtinib
Catalog No.:BCC2440
CAS No.:111358-88-4
- LY2784544
Catalog No.:BCC2200
CAS No.:1229236-86-5
- 1,2,3,4,5,6-Hexabromocyclohexane
Catalog No.:BCC2437
CAS No.:1837-91-8
- Cucurbitacin I
Catalog No.:BCC2439
CAS No.:2222-07-3
- SB1317
Catalog No.:BCC1925
CAS No.:937270-47-8
- SD 1008
Catalog No.:BCC2442
CAS No.:960201-81-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1271022-90-2 | SDF | Download SDF |
PubChem ID | 50922691 | Appearance | Powder |
Formula | C23H28N8O | M.Wt | 432.52 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 25 mg/mL (57.80 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
SMILES | CCN1C(=CC2=C3C(=C(N=C21)NC4=NN(C(=C4)C)C)N=CN3C)C(=O)N(C5CC5)C6CC6 | ||
Standard InChIKey | JCINBYQJBYJGDM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C23H28N8O/c1-5-30-17(23(32)31(14-6-7-14)15-8-9-15)11-16-20-19(24-12-28(20)3)21(26-22(16)30)25-18-10-13(2)29(4)27-18/h10-12,14-15H,5-9H2,1-4H3,(H,25,26,27) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | BMS-911543 is a selective small-molecule inhibitor of Janus tyrosine kinase 2 (JAK2) with IC50 value of 1 nM. | |||||
Targets | JAK2 | |||||
IC50 | 1 nM |
BMS-911543 Dilution Calculator
BMS-911543 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.312 mL | 11.5602 mL | 23.1203 mL | 46.2406 mL | 57.8008 mL |
5 mM | 0.4624 mL | 2.312 mL | 4.6241 mL | 9.2481 mL | 11.5602 mL |
10 mM | 0.2312 mL | 1.156 mL | 2.312 mL | 4.6241 mL | 5.7801 mL |
50 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 0.9248 mL | 1.156 mL |
100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.4624 mL | 0.578 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
BMS-911543 is a selective small-molecule inhibitor of JAK2 with IC50 value of 1.1nM [1].
BMS-911543 is a reversible pyrrolopyridine ATP-competitive JAK2 inhibitor with a high selectivity. In the in vitro assay using human recombinant JAK enzyme, BMS-911543 displays an IC50 value of 1.1nM against JAK2 and the Ki value is 0.48nM. The inhibition activity and affinity against JAK2 are both much higher than those against JAK1 and JAK3. Besides that, BMS-911543 also has efficacy against other kinases, such as Lyn and the c-FMS receptor tyrosine kinase. In JAK-dependent cells such as SET2 or Ba/F3, the treatment of BMS-911543 causes an anti-proliferative effect with IC50 values of 60 and 70nM, respectively. The cell lines depending on other JAK family members do not show significant anti-proliferative response to BMS-911543. The colony growth assays prove that BMS-911543 can suppress the growth of MPN patient-derived cells and is more potent in the JAK2V617F pathway compared with the JAK2WT pathway. BMS-911543 is also found to be potent in vivo in both the JAK2WT pathway and the JAK2V617F pathway through suppressing pSTAT5 induction [1].
References:
[1] Purandare AV, McDevitt TM, Wan H, You D, Penhallow B, Han X, Vuppugalla R, Zhang Y, Ruepp SU, Trainor GL, Lombardo L, Pedicord D, Gottardis MM, Ross-Macdonald P, de Silva H, Hosbach J, Emanuel SL, Blat Y, Fitzpatrick E, Taylor TL, McIntyre KW, Michaud E, Mulligan C, Lee FY, Woolfson A, Lasho TL, Pardanani A, Tefferi A, Lorenzi MV. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8.
- Glyceryl hexacosanoate
Catalog No.:BCC8991
CAS No.:127098-14-0
- Sulfo-NHS-LC-Biotin
Catalog No.:BCC3578
CAS No.:127062-22-0
- CGP 42112
Catalog No.:BCC5921
CAS No.:127060-75-7
- 4,9-Dimethoxycanthin-6-one
Catalog No.:BCN3107
CAS No.:1270001-72-3
- Beta-Pinene
Catalog No.:BCC8302
CAS No.:127-91-3
- Sulfamerazine
Catalog No.:BCC4854
CAS No.:127-79-7
- Sulfisoxazole
Catalog No.:BCC4860
CAS No.:127-69-5
- Sulfamerazine sodium salt
Catalog No.:BCC5205
CAS No.:127-58-2
- Sulfacetamide Sodium
Catalog No.:BCC4383
CAS No.:127-56-0
- 2,2-Bis(4-hydroxy-3-isopropylphenyl)propane
Catalog No.:BCC8494
CAS No.:127-54-8
- Vitamin A Acetate
Catalog No.:BCC4748
CAS No.:127-47-9
- Lutein
Catalog No.:BCN6151
CAS No.:127-40-2
- MI-3
Catalog No.:BCC1747
CAS No.:1271738-59-0
- MI-2
Catalog No.:BCC1746
CAS No.:1271738-62-5
- 4-O-Demethylkadsurenin D
Catalog No.:BCN6649
CAS No.:127179-70-8
- 7-(2'-Deoxyadenosin-N6-yl)aristolactam I
Catalog No.:BCN2559
CAS No.:127191-86-0
- KN-62
Catalog No.:BCC3602
CAS No.:127191-97-3
- (3S,4S)-3-(Boc-amino)-4-methylpyrrolidine
Catalog No.:BCC4015
CAS No.:127199-54-6
- Bisacurone C
Catalog No.:BCN7316
CAS No.:127214-86-2
- Intermedin B
Catalog No.:BCN7317
CAS No.:127214-87-3
- Sitafloxacin
Catalog No.:BCC5164
CAS No.:127254-12-0
- Balofloxacin
Catalog No.:BCC4892
CAS No.:127294-70-6
- BRL 37344, sodium salt
Catalog No.:BCC6860
CAS No.:127299-93-8
- Zamifenacin fumarate
Catalog No.:BCC7418
CAS No.:127308-98-9
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.[Pubmed:25912019]
Exp Hematol. 2015 Jul;43(7):537-45.e1-11.
Activation of Janus kinase 2 (JAK2), frequently as a result of the JAK2(V617F) mutation, is a characteristic feature of the classical myeloproliferative neoplasms (MPNs) polycythemia vera, essential thrombocythemia, and myelofibrosis, and it is thought to be responsible for the constitutional symptoms associated with these diseases. BMS-911543 is a JAK2-selective inhibitor that induces apoptosis in JAK2-dependent cell lines and inhibits the growth of CD34(+) progenitor cells from patients with JAK2(V617F)-positive MPN. To explore the clinical potential of this inhibitor, we tested BMS-911543 in a murine retroviral transduction-transplantation model of JAK2(V617F) MPN. Treatment was initiated at two dose levels (3 mg/kg and 10 mg/kg) when the hematocrit exceeded 70%. Following the first week, white blood cell counts were reduced to normal in the high-dose group and were maintained well below the levels in vehicle-treated mice throughout the study. However, BMS-911543 had no effect on red blood cell parameters. After 42 days of treatment, the proportion of JAK2(V617F)-positive cells in hematopoietic tissues was identical or slightly increased compared with controls. Plasma concentrations of interleukin 6, interleukin 15, and tumor necrosis factor alpha were elevated in MPN mice and reduced in the high-dose treatment group, whereas other cytokines were unchanged. Inhibitor activity after dosing was confirmed in a cell culture assay using the plasma of dosed mice and phosphorylated signal transducer and activator of transcription 5 flow cytometry. Collectively, these results show that BMS-911543 has limited activity in this murine model of JAK2(V617F)-driven MPN and suggest that targeting JAK2 alone may be insufficient to achieve effective disease control.
Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.[Pubmed:26575024]
Oncotarget. 2015 Dec 29;6(42):44509-22.
The Jak/STAT pathway is activated in human pancreatic ductal adenocarcinoma (PDAC) and cooperates with mutant Kras to drive initiation and progression of PDAC in murine models. We hypothesized that the small-molecule Jak2 inhibitor (BMS-911543) would elicit anti-tumor activity against PDAC and decrease immune suppressive features of the disease. We used an aggressive genetically engineered PDAC model with mutant KrasG12D, tp53R270H, and Brca1 alleles (KPC-Brca1 mice). Mice with confirmed tumor burden were treated orally with vehicle or 30 mg/kg BMS-911543 daily for 14 days. Histologic analysis of pancreata from treated mice revealed fewer foci of adenocarcinoma and significantly decreased Ki67+ cells versus controls. In vivo administration of BMS-911543 significantly reduced pSTAT5 and FoxP3 positive cells within the pancreas, but did not alter STAT3 phosphorylation. Continuous dosing of KPC-Brca1 mice with BMS-911543 resulted in a median survival of 108 days, as compared to a median survival of 87 days in vehicle treated animals, a 23% increase (p = 0.055). In vitro experiments demonstrated that PDAC cell lines were poorly sensitive to BMS-911543, requiring high micromolar concentrations to achieve targeted inhibition of Jak/STAT signaling. Similarly, BMS-911543 had little in vitro effect on the viability of both murine and human PDAC-derived stellate cell lines. However, BMS-911543 potently inhibited phosphorylation of pSTAT3 and pSTAT5 at low micromolar doses in human PBMC and reduced in vitro differentiation of Foxp3+ T regulatory cells. These results indicate that single agent Jak2i deserves further study in preclinical models of PDAC and has distinct inhibitory effects on STAT5 mediated signaling.
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.[Pubmed:26288683]
ACS Med Chem Lett. 2015 Jul 12;6(8):850-5.
JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway. X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole 1 led to the discovery of a clinical candidate, BMS-911543 (11), with excellent kinome selectivity, in vivo PD activity, and safety profile.
A UHPLC-MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma.[Pubmed:25930207]
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jun 1;991:85-91.
Herein we report a rapid, accurate and robust UHPLC-MS/MS assay for the quantitation of BMS-911453, a Janus kinase 2 inhibitor under clinical development for the treatment of myeloproliferative disorders, in human plasma. A systematic method development approach was used to optimize the mass spectrometry, chromatography, and sample extraction conditions, and to minimize potential bioanalytical risks. The validated method utilizes stable-isotope labeled (13)C4-BMS-911543 as the internal standard. Liquid-liquid extraction was used for sample preparation. Chromatographic separation was achieved within 2min on a Zorbax Extend-C18 column with an isocratic elution. BMS-911543 and its internal standard were detected by positive ion electrospray tandem mass spectrometry. The assay range was from 1 to 500ng/mL, and the standard curve was fitted with 1/x(2) weighted linear regression. The intra-assay precision was within 5.0% CV and the inter-assay precision was within 2.6% CV. The inter-assay mean accuracy, expressed as percents of theoretical, was between 99.8% and 102.3%. The assay has high recovery ( approximately 80%) and minimal matrix effect (0.95-1.00). BMS-911543 was stable in human plasma for at least 24h at room temperature, 90 days at -20 degrees C, and following three freeze-thaw cycles. The validated method was successfully applied to sample analysis in clinical studies.